These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 9877264

  • 1. A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis.
    Snowden JA, Biggs JC, Milliken ST, Fuller A, Staniforth D, Passuello F, Renwick J, Brooks PM.
    Bone Marrow Transplant; 1998 Dec; 22(11):1035-41. PubMed ID: 9877264
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation.
    Kröger N, Renges H, Krüger W, Gutensohn K, Löliger C, Carrero I, Cortes L, Zander AR.
    Br J Haematol; 2000 Dec; 111(3):761-5. PubMed ID: 11122135
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S, Arpaci F, Turan M, Solchaga L, Cetin T, Ozturk M, Ozet A, Komurcu S, Ozturk B.
    Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma: a temporal analysis of CD34(+) absolute counts and subsets.
    Chin-Yee IH, Keeney M, Stewart AK, Belch A, Bence-Buckler I, Couban S, Howson-Jan K, Rubinger M, Stewart D, Sutherland R, Paragamian V, Bhatia M, Foley R.
    Bone Marrow Transplant; 2002 Dec; 30(12):851-60. PubMed ID: 12476276
    [Abstract] [Full Text] [Related]

  • 8. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: results of an open study to assess feasibility, safety, and efficacy.
    Verburg RJ, Kruize AA, van den Hoogen FH, Fibbe WE, Petersen EJ, Preijers F, Sont JK, Barge RM, Bijlsma JW, van de Putte LB, Breedveld FC, van Laar JM.
    Arthritis Rheum; 2001 Apr; 44(4):754-60. PubMed ID: 11315914
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim.
    van Der Auwera P, Platzer E, Xu ZX, Schulz R, Feugeas O, Capdeville R, Edwards DJ.
    Am J Hematol; 2001 Apr; 66(4):245-51. PubMed ID: 11279634
    [Abstract] [Full Text] [Related]

  • 11. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
    Jacoub JF, Suryadevara U, Pereyra V, Colón D, Fontelonga A, Mackintosh FR, Hall SW, Ascensão JL.
    Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
    [Abstract] [Full Text] [Related]

  • 14. Mobilisation of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (Filgrastim) in patients with malignant lymphomas or solid tumours.
    Baars JW, Holtkamp MJ, Nooyen WJ, Walll EV, Te Velde A, Dalesio O, Slaper-Cortenbach IC, Schoot EV, Richel DJ, Gerritsen WR, Schornagel JH, Rodenhuis S.
    Anticancer Res; 1996 Nov; 16(5B):3089-95. PubMed ID: 8920773
    [Abstract] [Full Text] [Related]

  • 15. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.
    Bence-Bruckler I, Bredeson C, Atkins H, McDiarmid S, Hamelin L, Hopkins H, Perry G, Genest P, Huebsch L.
    Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693
    [Abstract] [Full Text] [Related]

  • 16. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors.
    Kroschinsky F, Hölig K, Poppe-Thiede K, Zimmer K, Ordemann R, Blechschmidt M, Oelschlaegel U, Bornhauser M, Rall G, Rutt C, Ehninger G.
    Haematologica; 2005 Dec; 90(12):1665-71. PubMed ID: 16330441
    [Abstract] [Full Text] [Related]

  • 17. Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies.
    Putkonen M, Rauhala A, Pelliniemi TT, Remes K.
    Ann Hematol; 2009 Jul; 88(7):673-80. PubMed ID: 19139894
    [Abstract] [Full Text] [Related]

  • 18. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 microg/kg) compared to a single dose (1 x 10 microg/kg).
    Kröger N, Zeller W, Hassan HT, Krüger W, Gutensohn K, Löliger C, Zander AR.
    Bone Marrow Transplant; 1999 Jan; 23(2):125-9. PubMed ID: 10197796
    [Abstract] [Full Text] [Related]

  • 19. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR.
    Snowden JA, Passweg J, Moore JJ, Milliken S, Cannell P, Van Laar J, Verburg R, Szer J, Taylor K, Joske D, Rule S, Bingham SJ, Emery P, Burt RK, Lowenthal RM, Durez P, McKendry RJ, Pavletic SZ, Espigado I, Jantunen E, Kashyap A, Rabusin M, Brooks P, Bredeson C, Tyndall A.
    J Rheumatol; 2004 Mar; 31(3):482-8. PubMed ID: 14994391
    [Abstract] [Full Text] [Related]

  • 20. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
    Russell N, Mesters R, Schubert J, Boogaerts M, Johnsen HE, Canizo CD, Baker N, Barker P, Skacel T, Schmitz N.
    Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.